Loading stock data…
$7.00+0.29 (+4.24%)
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$93.39M↓ | -$87.34M↓ | -$83.17M↓ | -$74.75M↑ | -$109.64M |
| Net Income | -$88.41M↓ | -$82.96M↓ | -$79.66M↓ | -$71.14M↑ | -$105.21M |
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to ...